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FOUND IN TRANSLATION
Surmounting structural barriers to tackle endemic
infectious diseases
Felix Calderón1, Alan H. Fairlamb2, Mike Strange1,4, Pauline Williams1,4, and Carl F. Nathan3
A unique experiment in bringing academic and industrial scientists together to tackle endemic infectious diseases has proved a
success. The Tres Cantos Open Lab Foundation, guided and advised by independent experts, funds extended stays of academics
at the campus of a pharmaceutical company, where they access the firm’s resources in partnership with company scientists.
Progress in tackling tuberculosis, protozoal infections, and enteric bacterial diseases has sustained the decade-long evolution
of the model, whose distinctive features complement other public–private partnerships with similar goals.
Malaria, tuberculosis, Chagas disease, leish-
maniasis, and enteric bacterial infections
disproportionally affect low- and middle-
income countries. The substantial global
burden of these diseases demands increased
drug development. However, difficulties
faced by academic innovators in gaining
access to industry-grade expertise and re-
sources in drug discovery are key structural
barriers to progress (Davis et al., 2021). The
conventional form of interaction was in-
efficient: scientists might report their
discoveries to their institutional technology
transfer offices, and drug developers might
license the discoveries. Thereafter, there
would be little communication or mutual
education between the academics and in-
dustry scientists. The past decade has seen
different organizational experiments to in-
crease the efficiency of such interactions
focused on diseases whose burdens fall most
heavily on low- and middle-income coun-
tries. Examples include the Medicines for
Malaria Venture, Drugs for Neglected Dis-
eases Initiative, and the Drug Accelerators
for tuberculosis and malaria, established by
the Bill and Melinda Gates Foundation,
which link members of academic and in-
dustrial sectors in virtual networks for
structured collaboration.
Here we describe a complementary ap-
proach to overcoming structural barriers to
drug development for endemic infectious
diseases—the Open Lab innovation model.
The Open Lab supports collaborative resi-
dencies for academics within a pharmaceu-
tical company. Established in 2010 by
GlaxoSmithKline (GSK), the Open Lab
model has proven its utility and durability
over the last decade (GlaxoSmithKline,
2010). A companion article in Nature Re-
views Drug Discovery describes the Open
Lab’s scientific accomplishments (Calderón
et al., 2021). Here we describe the Open
Lab’s approach and the organizational
structure that sustains it.
The Open Lab is an experimental col-
laborative initiative centered at GSK’s Tres
Cantos R&D Campus in Spain, offering re-
searchers in endemic infectious diseases
access to GSK’s core capabilities and exper-
tise in drug discovery (Tres Cantos Open
Lab Foundation, 2019b). Unlike the Drug
Accelerators, where membership is by in-
vitation, anyone can apply to the Open Lab.
In contrast to the Medicines for Malaria
Venture, Drugs for Neglected Diseases Ini-
tiative, and the Drug Accelerators, the Open
Lab involves extended, person-to-person en-
gagement between academics and industry
scientists colocated in the same laboratory at
a pharmaceutical company campus. The aca-
demic team retains ownership of the project,
and any intellectual property arising from the
Open Lab projects must be shared in a
“knowledge pool” with publication of key
data supporting drug discovery.
Projects are selected for the Open Lab
by the Tres Cantos Open Lab Foundation
(TCOLF), a charity established in the UK and
governed by an independent board of di-
rectors. TCOLF provides funding to cover
salaries, accommodation, travel expenses,
and relocation services for academics whose
projects are selected. GSK provides admin-
istrators, scientists, and technical staff who
engage with the project teams, along with
covering in-kind research costs for labora-
tory space, equipment, materials, and sup-
port services.
An independent scientific board of in-
fectious disease experts reviews Open
Lab applications (Tres Cantos Open Lab
Foundation, 2019a). Projects are evaluated
with respect to the following four parame-
ters: (1) high quality innovation—the ap-
plication must be scientifically thorough
and rigorous, show clear objectives, and in-
troduce new ideas, methods, or hypotheses;
(2) feasibility—theremust be a clear plan for
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progression at the Open Lab; (3) significance—
there must be a reasonable prospect for a
positive impact on the global health pipeline;
and (4) alignment with the Open Lab concept
and policies—the proposal needs to explain
how the project will benefit from on-site col-
laboration with an industry-based team, and
the applicant’s institution must accept Open
Lab policies regarding intellectual property
and publication.
The Open Lab aims to bridge the trans-
lational gap between fundamental scientific
exploration and the discovery of new med-
icines, spanning the so-called “valley of
death” where 90% of promising ideas for
clinical intervention are lost (Barohn et al.,
2019; Seyhan, 2019; Truebel and Thurston,
2020). As the relationship between funda-
mental and applied research has matured,
the nature of accepted proposals has evolved.
At first, the selected projects focused on
discovering early drug candidates. Later,
priorities broadened to include methods
for shortening treatments, tools for sup-
porting disease eradication, novel drug
combinations, disruptive target-based pro-
grams, validation of new phenotypes, and
the development of more physiologically
relevant disease models.
Before projects reach the Open Lab, GSK
scientists offer a period of less formal col-
laboration to allow for the exchange of ideas
and guide the design of more competitive
proposals. Informally termed “pre-Open
Lab,” this can include experimental work,
proof-of-concept studies, or simulations.
This period is critical not just to generate
data, but to define clear objectives and en-
gender alignment for collaborative success.
Cross-disciplinary teamwork and the desire
to solve real-world problems that impact
patients are the most important factors in
ensuring progress.
Most Open Lab fellows are postdoc-
toral scientists from academia. Although
the Open Lab is not designed as a train-
ing program, the experience advances
investigators’ scientific education, provides
visibility of opportunities available in both
industry and academia, and fosters a new
generation of global health scientists with
wide-ranging knowledge of their field and
an awareness of the capabilities of industry
to deliver new medicines.
Key to the Open Lab approach is the
alignment of its activities to best serve the
community. This is encompassed within
three main areas. (1) Intellectual property.
All Open Lab projects follow the principles
of World Intellectual Property Organization
(WIPO) Re:Search, a public–private part-
nership administered by WIPO in collabo-
ration with BIO Ventures for Global Health
(https://www.wipo.int/research/en/).
WIPO Re:Search allows organizations to
share their intellectual property, expertise,
facilities, and know-how royalty-free with
qualified researchers worldwide working on
new solutions for neglected tropical dis-
eases, malaria, and tuberculosis. (2) Collab-
orator colocation. The usual model of
industry–academia collaborations is based
on combining the technical expertise of each
partner and sharing information in meet-
ings and in written form. In contrast, the
Open Lab allows colocation of researchers
from each organization in the same labora-
tory in Tres Cantos. This catalyzes the ex-
change of ideas and information, enhancing
the thriving scientific community in Tres
Cantos by bringing diversity of thought and
culture and enriching the collaborative ex-
perience. Informal exchange of ideas on a
day-to-day basis allows any issues to be
addressed promptly. Although communica-
tions within a particular project are exten-
sive, conversations among investigators from
Distribution of institutions that have participated in the Open Lab model.
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different institutions have been more cau-
tious, perhaps reflecting an academic culture
of prepublication competition. Because ex-
panding cross-project interactions is likely to
be fruitful, the Open Lab is striving to create a
sheltered environment for the safe inter-
mingling of different project groups. (3) Fi-
nancial independence. The TCOLF board of
directors independently decides where and
when to invest. GSK has provided financial
support to TCOLF—a total of £15 million in
three tranches (2010, 2012, and 2018). Ap-
plications are straightforward, comprising
responses to 11 questions. With three TCOLF
Board meetings a year, applications receive
feedback and a decision within 4 mo. These
provisions ensure that investigators are not
burdened with excessive administrative re-
quirements and that there is flexibility within
the system to make rapid decisions on fund-
ing so that projects are not delayed.
The orientation of the Open Lab toward
providing the best possible experience for
investigators has driven high demand, with
more than 85 projects approved and im-
plemented since 2011, coming from 75 dif-
ferent institutions in 20 countries. Over 100
academic scientists have progressed their
projects, benefiting from access to GSK’s
screening platforms, medicinal chemistry,
ADMET tests (absorption, distribution, me-
tabolism, excretion, and toxicology), animal
models, assay development expertise, and
target validation platforms. In particular, the
Open Lab offers investigators opportunities
not available at many academic institutions,
such as biosecurity level 3 in vitro and
in vivo laboratories and an insectary. These
efforts have resulted in the publication of
hundreds of validated hits, the characteri-
zation of structure–function relationships
for more than 20 novel chemical scaffolds,
including a novel clinical candidate, as well
as the evaluation of drug-repurposing op-
portunities. Moreover, the innovative na-
ture of the projects has required the
development of novel screening assays, dis-
covery platforms, and in vitro and in vivo
models.
This year marks 10 yr since the first
Open Lab project started. It has been a de-
cade of transformation in global health. We
now have clear mandates that define the
scientific agenda across neglected infectious
diseases. Accomplishing this agenda re-
quires us to depart from conventional mod-
els of drug and vaccine development and
continually reevaluate our policies, pro-
cesses, and approach to risk. It is uncommon
for any industry initiative to last for 10 yr,
even more so if it involves collaboration. For
example, within the TB Drug Accelerator,
which is likewise celebrating its 10th anni-
versary, there have been changes in the list
of participants from the pharmaceutical
sector along the years (Aldridge et al., 2021).
Moreover, even with the rapidly evolving
nature of the industry with periodic review
of priorities—and GSK is no exception—the
Open Lab has persisted and thrived.
The Open Lab continues to surprise and
deliver as a rapid testbed for new ideas and
as a unique experiment in effective cross-
disciplinary collaboration. Ongoing chal-
lenges include the adaptation of themodel to
accommodate projects aligned with needs in
the field and to increase the geographical
diversity of applications. Looking ahead to
the next 10 yr, we envisage the prophylactic
and therapeutic pipeline for endemic infec-
tious diseases continuing to increase in
scope and quality and to deliver new tools
and approaches that improve human health
around the globe.
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